The trial will evaluate the effectiveness and safety of a new vaccine compared to an FDA-approved mRNA vaccine.
University of Georgia-based startup CyanVac LLC has received federal funding to conduct a Phase 2b clinical trial to compare its intranasal vaccine candidates, CVXGA, which are designed to provide protection against COVID-19.
As part of the award from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services (HHS), CyanVac will sponsor a randomized, double-blind Phase 2b study with 10,000 participants to compare the efficacy and safety of the intranasal vaccine against an FDA-approved mRNA-based COVID-19 vaccine.
The new vaccine is based on a viral delivery platform developed by He containing modified strains of parainfluenza virus 5, which causes kennel cough in dogs but is relatively harmless to humans.
Parainfluenza virus 5 (PIV5) is a member of the Paramyxoviridae family known to infect dogs, leading to respiratory illnesses similar to kennel cough. It can also infect other mammals, including humans, typically causing mild respiratory symptoms. The virus is airborne and spreads through respiratory droplets, necessitating good hygiene and isolation practices to control outbreaks.
CyanVac’s Commitment and Project Goals
CyanVac was founded by Biao He, Regents’ Entrepreneur, Fred C. Davison Distinguished University Chair in Veterinary Medicine and a faculty member in UGA’s College of Veterinary Medicine (CVM). He served on a White House panel to advise on the future of COVID-19 vaccines and was named both UGA Inventor and Entrepreneur of the Year.
Biao He in his laboratory. Credit: Andrew Davis Tuckert
“We are very excited about this opportunity to test a novel intranasal COVID vaccine whose technology platform has been developed at UGA,” said He, who is based in UGA’s Department of Infectious Diseases. “The name of our vaccine—CVXGA—is a tribute to UGA and CVM whose support over the years made this possible.”
Project NextGen’s goal is to advance new, innovative vaccines and therapeutics that provide longer-lasting and more durable protection against COVID-19. The award is one of the first made through the Rapid Response Partnership Vehicle, a consortium funded by the HHS Biomedical Advanced Research and Development Authority (BARDA) to accelerate product and technology development.
The Phase 2b study, which will begin this fall, will be carried out by BARDA’s Clinical Studies Network, focusing on evaluating the vaccine in a subset of participants who are at a higher risk of severe disease.
News
AI Struggles with Abstract Thought: Study Reveals GPT-4’s Limits
While GPT-4 performs well in structured reasoning tasks, a new study shows that its ability to adapt to variations is weak—suggesting AI still lacks true abstract understanding and flexibility in decision-making. Artificial Intelligence (AI), [...]
Turning Off Nerve Signals: Scientists Develop Promising New Pancreatic Cancer Treatment
Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost treatment effectiveness. Pancreatic cancer is closely linked to the nervous system, according to researchers from the [...]
New human antibody shows promise for Ebola virus treatment
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics. [...]
Early Alzheimer’s Detection Test – Years Before Symptoms Appear
A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving early Alzheimer’s diagnosis. Unlike amyloid-beta, tau neurofibrillary tangles are directly linked to cognitive decline. Years [...]
New mpox variant can spread rapidly across borders
International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly. The mpox virus [...]
How far would you trust AI to make important decisions?
From tailored Netflix recommendations to personalized Facebook feeds, artificial intelligence (AI) adeptly serves content that matches our preferences and past behaviors. But while a restaurant tip or two is handy, how comfortable would you [...]
Can AI Really Think? Research Reveals Gaps in Logical Execution
While AI models can break down problems into structured steps, new research reveals they still fail at basic arithmetic and fact-checking—raising questions about their true reasoning abilities. Large Language Models (LLMs) have become indispensable [...]
Scientists Just Made Cancer Radiation Therapy Smarter, Safer, and More Precise
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation while sparing healthy tissues. By using a KRAS-targeting drug to mark cancer cells and attaching a radioactive [...]
Superbugs Are Losing to Science, Light, and a Little Spice
Texas A&M researchers have found that curcumin, when activated by light, can weaken antibiotic-resistant bacteria, restoring the effectiveness of conventional antibiotics. Curcumin: A Surprising Ally Against Superbugs In 2017, a woman admitted to a [...]
New Research Shatters the Perfect Pitch Myth
For decades, people believed absolute pitch was an exclusive ability granted only to those with the right genetics or early music training. But new research from the University of Surrey proves otherwise. It’s been [...]
Why Some Drinkers Suffer Devastating Liver Damage While Others Don’t
A study from Keck Medicine of USC found that heavy drinkers with diabetes, high blood pressure, or a large waistline are up to 2.4 times more likely to develop advanced liver disease. These conditions may amplify [...]
“Good” Cholesterol Could Be Bad for Your Eyes – New Study Raises Concerns
‘Good’ cholesterol may be linked to an increased risk of glaucoma in individuals over 55, while, paradoxically, ‘bad’ cholesterol may be associated with a lower risk. These findings challenge conventional beliefs about factors that [...]
Reawakening Dormant Nerve Cells: Groundbreaking Neurotechnology Restores Motor Function
A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and improving movement. In a pilot clinical trial, three patients who received spinal cord stimulation for one [...]
AI’s Energy Crisis Solved? A Revolutionary Magnetic Chip Could Change Everything
AI is evolving at an incredible pace, but its growing energy demands pose a major challenge. Enter spintronic devices—new technology that mimics the brain’s efficiency by integrating memory and processing. Scientists in Japan have [...]
Nanotechnology for oil spill response and cleanup in coastal regions
(Nanowerk News) Cleaning up after a major oil spill is a long, expensive process, and the damage to a coastal region’s ecosystem can be significant. This is especially true for the world’s Arctic region, [...]
The Role of Nanotechnology in Space Exploration
Nanotechnology, which involves working with materials at the atomic or molecular level, is becoming increasingly important in space exploration. By improving strength, thermal stability, electrical conductivity, and radiation resistance, nanotechnology is helping create lighter, more [...]
